Zhaoke Ophthalmology-B Receives Australian Regulatory Submission Acceptance for Atropine Eye Drop Evaluation

Stock News

Jun 15

Zhaoke Ophthalmology-B (06622) has announced that on June 2, 2026, Australia's Therapeutic Goods Administration has accepted for review the company's registration application for its atropine sulfate eye drops (0.02% dose, product code: NVK002), which are used to slow the progression of myopia in children. The regulatory body has formally notified the company that its application has passed preliminary review and will proceed to a full evaluation. This application is based on the supportive results obtained from the company's Phase III clinical trial. The atropine sulfate eye drops (NVK002) are a solution intended to decelerate the worsening of myopia in children and adolescents. NVK002 is a patented formulation that effectively addresses the instability issues associated with low-concentration atropine. This technology is protected by intellectual property rights globally. The eye drops are preservative-free and have an anticipated shelf life of 24 months.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1117126120"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117126120\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117126120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 12:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117126120","market":"us","top_or_hot":-1,"title":"Zhaoke Ophthalmology-B Receives Australian Regulatory Submission Acceptance for Atropine Eye Drop Evaluation","media":"Stock News","content":"<p><b>Zhaoke Ophthalmology-B</b> (<b>06622</b>) has announced that on June 2, 2026, Australia's Therapeutic Goods Administration has accepted for review the company's registration application for its atropine sulfate eye drops (0.02% dose, product code: NVK002), which are used to slow the progression of myopia in children. The regulatory body has formally notified the company that its application has passed preliminary review and will proceed to a full evaluation. This application is based on the supportive results obtained from the company's Phase III clinical trial. The atropine sulfate eye drops (NVK002) are a solution intended to decelerate the worsening of myopia in children and adolescents. NVK002 is a patented formulation that effectively addresses the instability issues associated with low-concentration atropine. This technology is protected by intellectual property rights globally. The eye drops are preservative-free and have an anticipated shelf life of 24 months.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology-B Receives Australian Regulatory Submission Acceptance for Atropine Eye Drop Evaluation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology-B Receives Australian Regulatory Submission Acceptance for Atropine Eye Drop Evaluation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-15 12:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Zhaoke Ophthalmology-B</b> (<b>06622</b>) has announced that on June 2, 2026, Australia's Therapeutic Goods Administration has accepted for review the company's registration application for its atropine sulfate eye drops (0.02% dose, product code: NVK002), which are used to slow the progression of myopia in children. The regulatory body has formally notified the company that its application has passed preliminary review and will proceed to a full evaluation. This application is based on the supportive results obtained from the company's Phase III clinical trial. The atropine sulfate eye drops (NVK002) are a solution intended to decelerate the worsening of myopia in children and adolescents. NVK002 is a patented formulation that effectively addresses the instability issues associated with low-concentration atropine. This technology is protected by intellectual property rights globally. The eye drops are preservative-free and have an anticipated shelf life of 24 months.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1117126120","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117126120","pubTimestamp":1781497097,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhaoke Ophthalmology-B (06622) has announced that on June 2, 2026, Australia's Therapeutic Goods Administration has accepted for review the company's registration application for its atropine sulfate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","06622":"兆科眼科-B","BK1583":"高瓴概念","BK1191":"制药","BK1587":"次新股"},"translate_title":"兆科眼科-B获澳大利亚监管提交接受阿托品滴眼液评价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1},"content_text":"Zhaoke Ophthalmology-B (06622) has announced that on June 2, 2026, Australia's Therapeutic Goods Administration has accepted for review the company's registration application for its atropine sulfate eye drops (0.02% dose, product code: NVK002), which are used to slow the progression of myopia in children. The regulatory body has formally notified the company that its application has passed preliminary review and will proceed to a full evaluation. This application is based on the supportive results obtained from the company's Phase III clinical trial. The atropine sulfate eye drops (NVK002) are a solution intended to decelerate the worsening of myopia in children and adolescents. NVK002 is a patented formulation that effectively addresses the instability issues associated with low-concentration atropine. This technology is protected by intellectual property rights globally. The eye drops are preservative-free and have an anticipated shelf life of 24 months.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}